Focus: Fate Therapeutics is a public biotech company specializing in stem cell-modulating therapeutics and cell therapy, headquartered in San Diego with a focus on allogeneic cell therapies for oncology and hematologic malignancies.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Best suited for scientists and clinical professionals seeking high-impact cell therapy development with moderate financial risk; less ideal for those requiring near-term revenue upside or clinical milestone visibility.
Help build intelligence for Fate Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Fate Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE) ChartMill
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by Brokerages MarketBeat
FATE Q4 2025 Earnings: Fate Therapeutics Inc. tops EPS estimates, reports no revenue - Trend Analysis - Cổng thông tin điện tử tỉnh Lào Cai
FATE Q4 2025 Earnings: Fate Therapeutics Inc. tops EPS estimates, reports no revenue - Trend Analysis Cổng thông tin điện tử tỉnh Lào Cai
Fate Therapeutics Inc stock (US3025491025): Is its iPSC platform strong enough to unlock biotech ups - AD HOC NEWS
Fate Therapeutics Inc stock (US3025491025): Is its iPSC platform strong enough to unlock biotech ups AD HOC NEWS
Fate Therapeutics Inc stock: Q2 2026 conferences signal active engagement - AD HOC NEWS
Fate Therapeutics Inc stock: Q2 2026 conferences signal active engagement AD HOC NEWS
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences - GlobeNewswire
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences GlobeNewswire
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo